Injective jumps 7.46% as Pineapple Financial invests and trading volume surges

Traders Union
All News
Crypto News
Injective jumps 7.46% to $3.69 today

Highlights

Injective completed a mainnet upgrade to enhance high-speed payments, tokenization, and decentralized finance use cases, improving network performance.
Pineapple Financial committed $2 million to Injective, signaling increased institutional participation and external treasury support for the ecosystem.
INJ trades at $3.69, above the 20-day MA but below the 50-day/200-day MAs, with a projected five-day range of $3.30–$3.95 amid weak weekly indicators.

Institutional investment and upgrade spur volume, support sentiment shift

Injective recently completed a mainnet upgrade aimed at boosting network performance for high-speed payments, tokenization, and decentralized finance use cases. Institutional participation strengthened as Pineapple Financial publicly committed $2 million to Injective, highlighting external treasury support and growing conviction in the ecosystem. These developments have increased trading volume and signal ongoing governance progress for Injective.

Conflicting momentum and overbought signals limit upside follow-through

Momentum indicators present a mixed outlook: while the Average Directional Index signals strong upward momentum, the MACD generates a strong sell signal that may caution against further immediate gains. The RSI, Commodity Channel Index, Bull/Bear Power, and Stochastic RSI all reflect overbought conditions, indicating buyers dominate intraday action, yet the Awesome Oscillator remains neutral. After an opening gap up from $3.43 to $3.78, INJ moderated to $3.69, closing near the middle of today's $3.60 – $3.78 range as volatility declined and price consolidated, with technical signals remaining conflicting.

Rangebound outlook persists as downside risk dominates

In the short term, INJ is likely to remain within a typical volatility band between $3.30 and $3.95. With all major weekly indicators pointing toward further weakness, the probability of a sustained price rise is below 20%. The baseline scenario anticipates continued rangebound movement, and a decisive move above $3.95 could challenge longer-term resistance, while a break below $3.30 would strengthen seller dominance and risk steeper declines.

Anton Kharitonov, expert at Traders Union, highlights that Injective shows short-term strength above its 20-day average, but the broader downtrend remains intact. He notes that despite the mainnet upgrade and fresh institutional backing, technical momentum is conflicting and sentiment is cautious. Rangebound movement is likely until clear confirmation either above $3.95 or below $3.30. "Base case remains range-trading — unless bulls reclaim $3.95, further upside looks limited."

Previously it was reported that Injective is exhibiting strong short-term bullish momentum, trading above its 20-day moving average yet remaining below key longer-term averages as upward movement meets resistance near the $3.60 level. Despite improved sentiment from governance upgrades and institutional interest, technical indicators including the daily MACD, ADX, and overbought Stoch RSI suggest mixed momentum and ongoing medium- to long-term selling pressure, with immediate support seen around $3.24.

Source of Data: INJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.